MARSHALL WACE, LLP - JUNO THERAPEUTICS INC ownership

JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 214 filers reported holding JUNO THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.99 and the average weighting 0.9%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of JUNO THERAPEUTICS INC
ValueSharesWeighting
Q4 2017$354,000
-66.9%
7,754
-78.3%
0.02%
-68.1%
Q2 2017$1,071,000
+73.6%
35,687
+120.3%
0.05%
+683.3%
Q1 2016$617,000
-81.1%
16,202
-74.1%
0.01%
-86.0%
Q4 2014$3,264,00062,5140.04%
Other shareholders
JUNO THERAPEUTICS INC shareholders Q3 2017
NameSharesValueWeighting ↓
Crestline Management, LP 25,948,799$1,132,937,000100.00%
Biomark Capital Management Co. LLC 1,602,562$70,465,00085.76%
Omega Fund Management, LLC 1,229,512$54,062,00030.09%
Clarius Group, LLC 218,942$9,626,0002.93%
BB BIOTECH AG 1,305,000$57,381,0001.62%
Casdin Capital, LLC 17,500$769,0000.68%
Rock Springs Capital Management LP 197,001$8,662,0000.66%
BENNETT LAWRENCE MANAGEMENT L L C/NY 38,850$1,708,0000.55%
ArrowMark Colorado Holdings LLC 383,749$16,873,0000.46%
SUFFOLK CAPITAL MANAGEMENT LLC 68,848$3,027,0000.38%
View complete list of JUNO THERAPEUTICS INC shareholders